Belgian venture capital firm HERAN Partners has successfully closed a €90 million fundraising round for its second healthtech investment vehicle, HERAN HealthTech Fund II, with plans to grow the fund closer to €110 million or €120 million in the coming period. The firm focuses on supporting early-stage medtech and healthtech companies across Europe that aim to make healthcare and life sciences research and development more efficient, data-driven, and scalable.
Key contributors to the fund include the European Investment Fund with a €20 million commitment and the Flemish investment company PMV, which has increased its participation to €10 million compared with the first fund. Other backers include entrepreneurs and management teams from HERAN’s first fund, as well as institutional partners such as BNP Paribas Fortis, Finance & Invest Brussels, and KU Leuven Research & Development.

HERAN’s first fund, which closed at €75.5 million, delivered multiple successful exits. Building on this track record, Fund II will continue to back seed and Series A companies developing enabling technologies across software, hardware, and services that support real-world healthcare needs. The team has also expanded with new partner appointments, and the fund has already made its first investment in Pharmacelera, a Spain-based company using advanced computing methods to accelerate drug discovery.